Drugs / Daunorubicin
last change 8 days ago re-read 8 days ago

Daunorubicin

Small molecule

Developed for
acute myeloid leukemia · leukemia · acute lymphoblastic leukemia · myelodysplastic syndrome · lymphoblastic lymphoma · childhood acute myeloid leukemia · lymphoma · myeloid leukemia
+56 more · therapy related acute myeloid leukemia and myelodysplastic syndrome · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myelomonocytic leukemia M4 · acute promyelocytic leukemia · adult acute lymphoblastic leukemia · childhood acute lymphoblastic leukemia · lymphoid leukemia · myelodysplastic/myeloproliferative neoplasm · acute basophilic leukemia · acute erythroid leukemia · acute monocytic leukemia · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia, inv(16)(p13.1;q22) · childhood acute megakaryoblastic leukemia · childhood myelodysplastic syndrome · refractory anemia with excess blasts in transformation · sarcoma · acquired polycythemia vera · acute leukemia · acute leukemia of ambiguous lineage · acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, biallelic CEBPA gene mutation · acute myeloid leukemia, FLT3 internal tandem duplication · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myeloid leukemia, t(8;21)(q22; q22.1) · acute myeloid leukemia, t(9;11)(p21.3;q23.3) · adult acute monocytic leukemia · anaplastic large cell lymphoma · B-cell acute lymphoblastic leukemia · B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma · breast cancer · Burkitt lymphoma · childhood malignant neoplasm · chronic myeloid leukemia · diffuse large B-cell lymphoma · essential thrombocythemia · hematopoietic and lymphoid cell neoplasm · Hodgkins lymphoma · Kaposi's sarcoma · mixed phenotype acute leukemia · myelofibrosis · myeloid leukemia associated with down syndrome · non-Hodgkin lymphoma · precursor B-cell acute lymphoblastic leukemia · T-cell acute lymphoblastic leukemia · urinary bladder cancer · urothelial carcinoma · acute megakaryoblastic leukemia in adult · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia with mutated NPM1 · acute myeloid leukemia, del(5q31-q32) · early T cell progenitor acute lymphoblastic leukemia
Investigated by
National Cancer Institute (NCI) · Children's Oncology Group · PETHEMA Foundation · St. Jude Children's Research Hospital · Institute of Hematology & Blood Diseases Hospital, China · Jazz Pharmaceuticals
+156 more · SWOG Cancer Research Network · GIMEMA Foundation · AbbVie · Deutsche Krebshilfe e.V., Bonn (Germany) · First Affiliated Hospital of Zhejiang University · Johann Wolfgang Goethe University Hospital · Medical Research Council · Memorial Sloan Kettering Cancer Center · Technical University Dresden · Acute Leukemia French Association · Alliance for Clinical Trials in Oncology · Assistance Publique - Hôpitaux de Paris · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Cooperative Study Group A for Hematology · Dutch Childhood Oncology Group · Eastern Cooperative Oncology Group · European Organisation for Research and Treatment of Cancer - EORTC · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · French Innovative Leukemia Organisation · Goethe University · HOVON Foundation · Hannover Medical School · Italian Association of Pediatric Hematology and Oncology · M.D. Anderson Cancer Center · Qilu Hospital of Shandong University · Roswell Park Cancer Institute · The First Affiliated Hospital of Anhui Medical University · Tongji Hospital · University Hospital Schleswig-Holstein · University Medical Center Hamburg-Eppendorf · AIDS Malignancy Consortium · AVEO Pharmaceuticals, Inc. · All India Institute of Medical Sciences · Anhui Medical University · Arog Pharmaceuticals, Inc. · Asan Medical Center · Astellas Pharma Global Development, Inc. · Australian and New Zealand Children's Oncology Group · BFM Austria · BFM Germany · Beat AML, LLC · Beijing 302 Hospital · Bhavana Bhatnagar · CLCG France Belgium Portugal · COALL Germany · CORS Monza Italy · CPH, Czech republic · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · CTI BioPharma · Celgene Corporation · Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · Children's Cancer Group, China · Children's Hospital Medical Center, Cincinnati · Children's Hospital of Philadelphia · Children's Hospital of Soochow University · Children's Mercy Hospital Kansas City · Copernicus Memorial Hospital · DFCI consortium USA · Dana-Farber Cancer Institute · Emory University · Ev. Krankenhaus Essen-Werden · FRALLE France · First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital, Sun Yat-Sen University · First Hospital of China Medical University · Fresenius Kabi · GWT-TUD GmbH · Genzyme, a Sanofi Company · Georgetown University · Gilead Sciences · Grupo Argentino de Tratamiento de la Leucemia Aguda · Guangdong Provincial People's Hospital · H. Lee Moffitt Cancer Center and Research Institute · Hoffmann-La Roche · all 162 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Vyxeos liposomal (previously Vyxeos) — 2018-08-23 europa.eu ↗
Label expansion US (FDA) CERUBIDINE — 1987-03-06 fda.gov ↗
Approved US (FDA) CERUBIDINE — 1979-12-19 fda.gov ↗

Trials 150 · started per year

today
US approved 1979
EU approved 2018
1
2
1
5
1
3
3
3
6
9
13
6
5
2
4
4
4
2
6
1
3
2
3
5
1
9
5
4
1
6
6
1
2
1
8
5
5
1
197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 113 trials
Phase 1 NCT05453903 Oct 2022 → Oct 2026 expected acute myeloid leukemia Janssen Research & Development, LLC Active not recruiting No outcome recorded
Phase 1 NCT05342584 May 2022 → Dec 2028 expected acute myeloid leukemia, myelodysplastic syndrome Montefiore Medical Center Recruiting No outcome recorded
Phase 1 NCT02971397 Nov 2016 → Mar 2018 acute myeloid leukemia Wake Forest University Health Sciences Completed No outcome recorded
Phase 1 NCT02914977 Nov 2016 → Apr 2019 acute lymphoblastic leukemia, acute myeloid leukemia Tara Lin Completed No outcome recorded
Phase 1 NCT02323607 Jan 2016 → Jul 2018 therapy related acute myeloid leukemia and myelodysplastic syndrome Bhavana Bhatnagar Completed No outcome recorded
Phase 1 NCT02632708 Dec 2015 → Dec 2018 overdue therapy related acute myeloid leukemia and myelodysplastic syndrome Servier Active not recruiting No outcome recorded
Phase 1 NCT02236013 Jan 2015 → Jul 2021 acute myeloid leukemia Astellas Pharma Global Development, Inc. Completed No outcome recorded
Phase 1 NCT01943682 Sep 2013 → Mar 2019 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Burkitt lymphoma, Hodgkins lymphoma, acute lymphoblastic leukemia +4 Children's Hospital Medical Center, Cincinnati Completed No outcome recorded
Phase 1 NCT00427414 Sep 2008 → Nov 2010 sarcoma AIDS Malignancy Consortium Terminated No outcome recorded Stop: Enrollment
Phase 1 NCT00389428 Sep 2006 → Dec 2008 hematopoietic and lymphoid cell neoplasm Jazz Pharmaceuticals Completed No outcome recorded
Phase 1/28 trials
Phase 1/2 NCT04990102 May 2023 → Dec 2026 expected acute myeloid leukemia Georgetown University Recruiting No outcome recorded
Phase 1/2 NCT04109690 Dec 2019 → Jul 2021 myelodysplastic syndrome Yale University Withdrawn No outcome recorded Stop: Enrollment
Phase 1/2 NCT03850535 Mar 2019 → Sep 2020 acute myeloid leukemia Hoffmann-La Roche Terminated No outcome recorded
Phase 1/2 NCT03878199 Feb 2019 → Feb 2025 acquired polycythemia vera, acute myeloid leukemia, essential thrombocythemia, myelofibrosis Ohio State University Comprehensive Cancer Center Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT00015860 May 2001 → Oct 2003 leukemia Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 1/2 NCT00219765 May 2001 → Jan 2006 chronic myeloid leukemia Poitiers University Hospital Terminated No outcome recorded
Phase 1/2 NCT00005793 Jul 1999 → Jul 2006 leukemia H. Lee Moffitt Cancer Center and Research Institute Completed No outcome recorded
Phase 1/2 NCT00002925 Feb 1997 → Nov 2003 leukemia National Cancer Institute (NCI) Completed No outcome recorded
Phase 246 trials · 1 met primary · 2 missed
Phase 2 NCT07862517 Jan → Dec 2027 expected acute myeloid leukemia National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT07548710 May 2026 → May 2027 expected acute myeloid leukemia Ruijin Hospital Recruiting No outcome recorded
Phase 2 NCT06770257 Dec 2025 → Dec 2026 acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Withdrawn No outcome recorded
Phase 2 NCT06930105 Sep 2025 → Nov 2027 expected acute lymphoblastic leukemia Xianmin Song, MD Not yet recruiting No outcome recorded
Phase 2 NCT07078591 Jun 2025 → Jun 2030 expected acute myeloid leukemia Beijing 302 Hospital Recruiting No outcome recorded
Phase 2 NCT05554406 Sep 2024 → Mar 2027 expected acute myeloid leukemia with multilineage dysplasia, therapy related acute myeloid leukemia and myelodysplastic syndrome National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT05554393 Sep 2024 → Dec 2027 expected acute myeloid leukemia National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT05564390 Jun 2024 → May 2029 expected acute myeloid leukemia with multilineage dysplasia, myelodysplastic syndrome National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT05904106 Apr 2024 → Sep 2028 expected acute myeloid leukemia Technical University Dresden Recruiting No outcome recorded
Phase 2 NCT05829434 Mar 2024 → Aug 2028 acute myeloid leukemia, myelodysplastic syndrome Uwe Platzbecker Withdrawn No outcome recorded
Phase 2/38 trials
Phase 2/3 NCT07651163 Mar 2026 → Dec 2029 expected acute myeloid leukemia First Affiliated Hospital of Zhejiang University Enrolling by invitation No outcome recorded
Phase 2/3 NCT07651176 Mar 2026 → Dec 2029 expected acute myeloid leukemia First Affiliated Hospital of Zhejiang University Enrolling by invitation No outcome recorded
Phase 2/3 NCT03013998 Nov 2016 → Dec 2032 expected acute myeloid leukemia Beat AML, LLC Recruiting No outcome recorded
Phase 2/3 NCT00454480 Aug 2006 → Aug 2012 leukemia, myelodysplastic syndrome The University of New South Wales Completed No outcome recorded
Phase 2/3 NCT00111345 Mar 2004 → Mar 2012 myeloid leukemia University Hospital Muenster Unknown No outcome recorded
Phase 2/3 NCT01015196 Jan 2001 → ? acute myeloid leukemia Nantes University Hospital Completed No outcome recorded
Phase 2/3 NCT00209833 Jan 1999 → Sep 2005 acute myeloid leukemia, refractory anemia with excess blasts in transformation Hannover Medical School Unknown No outcome recorded
Phase 2/3 NCT00002499 Jan 1990 → ? leukemia Grupo Argentino de Tratamiento de la Leucemia Aguda Unknown No outcome recorded
Phase 344 trials · 2 met primary · 2 missed
Phase 3 NCT07232134 Jul 2025 → Jul 2030 expected Down syndrome, acute myeloid leukemia Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting No outcome recorded
Phase 3 NCT06182592 Jan 2024 → Feb 2026 overdue acute myeloid leukemia CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT04184505 Nov 2020 → Mar 2026 overdue myelodysplastic syndrome GIMEMA Foundation Recruiting No outcome recorded
Phase 3 NCT04293562 Jul 2020 → Jun 2029 expected acute myeloid leukemia Children's Oncology Group Recruiting No outcome recorded
Phase 3 NCT03507842 Mar 2018 → Dec 2028 expected acute myeloid leukemia Asan Medical Center Enrolling by invitation No outcome recorded
Phase 3 NCT03007147 Aug 2017 → Jun 2026 overdue B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia Children's Oncology Group Active not recruiting No outcome recorded
Phase 3 NCT02845882 Jan 2016 → Dec 2023 overdue lymphoblastic lymphoma Children's Cancer Group, China Active not recruiting No outcome recorded
Phase 3 NCT02521493 Dec 2015 → Jun 2024 overdue Down syndrome, myelodysplastic syndrome, myeloid leukemia associated with down syndrome Children's Oncology Group Active not recruiting No outcome recorded
Phase 3 NCT02072811 Feb 2014 → Feb 2018 acute myeloid leukemia dr hab. n. med. Agnieszka Wierzbowska Unknown No outcome recorded
Phase 3 NCT02070523 Dec 2013 → Nov 2015 acute lymphoblastic leukemia Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. Unknown No outcome recorded
Phase 413 trials · 2 met primary
Phase 4 NCT01987297 Jun 2012 → Dec 2020 acute promyelocytic leukemia Shanghai Jiao Tong University School of Medicine Unknown Met primary
Phase 4 NCT02894645 Oct 2008 → Oct 2018 childhood acute lymphoblastic leukemia National University Hospital, Singapore Unknown Met primary
Phase 4 NCT02036489 Jan 2008 → Dec 2019 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00526409 Jun 2005 → Oct 2014 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00180167 Jan 2005 → Jul 2010 acute myeloid leukemia Technical University Dresden Completed No outcome recorded
Phase 4 NCT00199017 Apr 2004 → Mar 2009 lymphoblastic lymphoma Johann Wolfgang Goethe University Hospital Completed No outcome recorded
Phase 4 NCT00853008 Jan 2003 → Nov 2012 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00526175 Jun 2001 → May 2015 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00526305 Jan 2000 → Apr 2005 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00180128 Jan 2000 → Nov 2012 acute promyelocytic leukemia Technical University Dresden Unknown No outcome recorded
Phase not applicable18 trials · 1 missed
— NCT07495631 Apr 2026 → Mar 2028 expected adult acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT07443592 Mar 2026 → Mar 2031 expected acute lymphoblastic leukemia PETHEMA Foundation Not yet recruiting No outcome recorded
— NCT06697327 Feb → Aug 2025 overdue acute myeloid leukemia Anhui Medical University Enrolling by invitation No outcome recorded
— NCT07131059 May 2024 → May 2026 overdue acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT04179929 Nov 2019 → Nov 2026 expected acute lymphoblastic leukemia PETHEMA Foundation Recruiting No outcome recorded
— NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
— NCT02519712 Jul 2015 → Sep 2017 acute myeloid leukemia Memorial Sloan Kettering Cancer Center Terminated No outcome recorded Stop: Enrollment
— NCT02432872 Apr 2015 → May 2018 acute myeloid leukemia Jianxiang Wang Unknown No outcome recorded
— NCT01156883 Apr 2010 → Oct 2017 leukemia GIMEMA Foundation Completed No outcome recorded
— NCT01953770 Feb 2008 → Jan 2015 childhood acute lymphoblastic leukemia Federal Research Institute of Pediatric Hematology, Oncology and Immunology Unknown No outcome recorded
Comparator or background therapy219 trials
Phase 0 NCT03568994 Background Jul 2018 → Sep 2020 acute myeloid leukemia Baylor College of Medicine Completed No outcome recorded
Phase 1 NCT07052994 Background May 2026 childhood leukemia M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1 NCT06313437 Background Dec 2024 → Mar 2027 expected acute myeloid leukemia Dana-Farber Cancer Institute Recruiting No outcome recorded
Phase 1 NCT05886049 Background Jun 2024 → Dec 2027 expected acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, MLL gene rearrangement National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1 NCT06226571 Background May 2024 → Feb 2027 expected acute myeloid leukemia Syndax Pharmaceuticals Active not recruiting No outcome recorded
Show all 219 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 9

DateIssuerRelease
2026-05-13 Kyowa Kirin, Inc. Results Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress – Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median follow-up – – Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028 – kyowakirin.com ↗
Composite complete response (CRc) rates of 96% (47/49) for NPM1-m and 90% (45/50) for KMT2A-r AML
2026-05-12 Kura Oncology, Inc. Results Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress kuraoncology.com ↗
Composite complete response (CRc) rates of 96% (47/49) for NPM1 -m and 90% (45/50) for KMT2A -r AML
2025-06-12 Kura Oncology, Inc. Results Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress kuraoncology.com ↗
2022-11-03 Jazz Pharmaceuticals Results Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research jazzpharma.com ↗
Preliminary results suggest the combination of Vyxeos + MID is feasible with a manageable safety profile and promising remission rates in adults with newly diagnosed, FLT3 -mutated AML.
2021-03-30 Jazz Pharmaceuticals Regulatory Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients jazzpharma.com ↗
With the expansion of the Vyxeos label to include the pediatric population, Jazz demonstrates our continued commitment to broadening our cancer research and focusing on the people for whom we can have the greatest impact.
2018-08-03 Jazz Pharmaceuticals Regulatory CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection jazzpharma.com ↗
The Vyxeos NTAP will support Medicare beneficiaries' access to Vyxeos when they are treated in certain inpatient hospital settings.
2017-11-03 Jazz Pharmaceuticals Regulatory Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia jazzpharma.com ↗
2017-08-03 Jazz Pharmaceuticals Regulatory Jazz Pharmaceuticals Announces FDA Approval of Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) jazzpharma.com ↗
Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the U.S. Food and Drug Administration (FDA) has approved Vyxeos™ (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of Acute Myeloid Leukemia (AML), a rapidly progressing and life-threatening blood cancer.
2016-12-04 Karyopharm Therapeutics Inc Results Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting karyopharm.com ↗
Data from this Phase 1 trial suggest that oral selinexor (80mg) twice weekly can be safely administered in combination with induction chemotherapy with cytarabine and daunorubicin in patients with poor-risk AML, including elderly patients.

All press releases naming this drug 11 releases

DateIssuerRelease

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 370 sources stand behind the page.

FieldValueCited text
Known as daunorubicin “In the control arm, patients received other physician-directed regimen including fludarabine, cytarabine with/without granulocyte stimulating factor(FLA±G) regimen,cytarabine...” NCT02937662 ↗
312

“Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is...” NCT06810791 ↗

“Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With...” NCT00180167 ↗

“Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day...” NCT03446638 ↗

“with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin,...” NCT04845035 ↗

“A Phase I-II Study of a Liposomal Formulation of Cytarabine and Daunorubicin (CPX-351) in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing...” NCT04109690 ↗

“CPX-351 is a formulation of two drugs, cytarabine and daunorubicin, that is administered as the first part of treatment to get rid of as many leukemia cells in your bone marrow...” NCT04209725 ↗

“Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available),...” NCT04501614 ↗

“For FLT3/IDH1 wild-type participants who are eligible for chemotherapy, Anthracycline: Daunorubicin (DNR) 45 mg/m² per day on Days 1-3, or Idarubicin (IDA) 6 mg/m² per day on Days 1-3.” NCT07548710 ↗

“Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.” NCT07454226 ↗

“Participants will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT07443592 ↗

Show 302 more sources

Known as Adriamycin “Daunorubicin, Adriamycin” NCT00199069 ↗
Known as Cerubidine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01015196 ↗
Known as Daunomycin “Daunorubicin, Daunomycin, DNM, DNR, NSC-82151” NCT01324063 ↗
8

“Daunomycin 20 mg/m2/week IV days 1,15” NCT00187057 ↗

NCT00085709 ↗

NCT07561892 ↗

NCT03021330 ↗

NCT00176462 ↗

NCT00610883 ↗

NCT00187122 ↗

NCT00136448 ↗

Known as daunorubicin hydrochloride “Patients receive dasatinib and dexamethasone as in RIT, cyclophosphamide IV on day 1, daunorubicin hydrochloride IV and vincristine sulfate IV on days 1 and 8” NCT01256398 ↗
64

“daunorubicin hydrochloride IV on days 1, 8, 15, and 22” NCT00558519 ↗

“daunorubicin hydrochloride (DNR) IV over 1 hour” NCT00550992 ↗

“daunorubicin hydrochloride [daunorubicin]” NCT05554393 ↗

“daunorubicin hydrochloride IV on days 1-3” NCT00061945 ↗

“Drug: daunorubicin hydrochloride” NCT00002756 ↗

“Drug: Daunorubicin Hydrochloride” NCT01253070 ↗

“Drug: daunorubicin hydrochloride” NCT00046930 ↗

“Drug: daunorubicin hydrochloride” NCT00121303 ↗

“Drug: daunorubicin hydrochloride” NCT00022737 ↗

“Drug: Daunorubicin Hydrochloride” NCT02521493 ↗

Show 54 more sources

Known as daunorubicin liposomal “Patients receive daunorubicin liposomal IV over a minimum of 2 hours on day 1.” NCT00004207 ↗
Known as Daunorubicine “1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)” NCT04184505 ↗
7

“3+7 (cytarabine and daunorubicine or idarubicine)” NCT06713837 ↗

NCT00209833 ↗

NCT00449319 ↗

NCT00428558 ↗

NCT00219765 ↗

NCT00589082 ↗

NCT00537550 ↗

Known as DaunoXome “DaunoXome (Liposomal Daunorubicin) Plus Ara-C Versus Daunorubicin Plus Ara-C in Elderly AML Patients.A Randomized Phase III Study.” NCT00589082 ↗
4

“Patients are randomly assigned to receive doxorubicin HCl liposome (Doxil) or daunorubicin (DaunoXome) in a 3:1 ratio.” NCT00002985 ↗

“In the first course there will be a randomisation for liposomal daunorubicin (DaunoXome®) to be added or not.” NCT00186966 ↗

NCT01117441 ↗

NCT01828489 ↗

Known as DNM “Daunorubicin, Daunomycin, DNM, DNR, NSC-82151” NCT01324063 ↗
Known as DNR “The study included 727 older patients with AML (median age, 67 years) treated in two idarubicin (IDA) versus daunorubicin (DNR) Acute Leukemia French Association trials.” PMID 23248249 ↗ Dec 2012
25

“Participants will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT07443592 ↗

“Patients will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT04179929 ↗

“To determine, compared with Daunorubicin(DNR), whether Pegylated liposomal doxorubicin (PLD) inducing higher complete remission (CR) rate” NCT02070523 ↗

“The patients were then randomly assigned to receive two courses of daunorubicin (DNR, no- Ara-C group) or DNR + Ara-C (Ara-C group).” PMID 29615003 ↗ Apr 2018

“Patients receive daunorubicin (DNR) IV over 15-30 minutes and vincristine (VCR) IV over 3-5 minutes on days 1, 8, 15, and 22” NCT00002514 ↗

“Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3” NCT00927498 ↗

“daunorubicin hydrochloride (DNR) once weekly in weeks 2-5” NCT00430118 ↗

“daunorubicin hydrochloride (DNR) once weekly in weeks 2-5” NCT00613457 ↗

“Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.” NCT02776605 ↗

“daunorubicin (DNR) IV over 1-4 hours on days 8 and 15” NCT00003728 ↗

Show 15 more sources

Known as liposomal cytarabine/daunorubicin ClinicalTrials.gov intervention name — accepted as the source's own label NCT03760445 ↗
Known as Liposomal daunorubicin “The main purpose of this study is to determine the efficacy and toxicity of liposomal daunorubicin when added to fludarabine, ara-C and G-CSF(FLAG) in children with relapsed...” NCT00186966 ↗
Known as NSC-34521 “NSC-34521 DNR Daunorubicin” NCT00002704 ↗
Known as NSC-82151 “Daunorubicin, Daunomycin, DNM, DNR, NSC-82151” NCT01324063 ↗
3

“Daunorubicin, DNR, NSC-82151” NCT00002499 ↗

“Daunorubicin, DNR, NSC-82151” NCT00002471 ↗

“DNR Daunorubicin, NSC-82151” NCT00002691 ↗

Action Inhibit “it inhibits p-beta-catenin S552 in humans.” NCT02914977 ↗
Modality Small molecule “Anthracycline” NCT05660473 ↗
Route Intravenous “daunorubicin (DNR) IV over 15-30 minutes” NCT00002514 ↗